Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Sumant Ramachandra Purchases 200,000 Shares

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Sumant Ramachandra bought 200,000 shares of the firm’s stock in a transaction that occurred on Friday, March 21st. The stock was acquired at an average cost of $0.58 per share, with a total value of $116,000.00. Following the transaction, the director now owns 200,000 shares of the company’s stock, valued at $116,000. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Lyell Immunopharma Trading Down 6.1 %

Shares of NASDAQ:LYEL traded down $0.03 during trading on Tuesday, hitting $0.53. 440,470 shares of the company were exchanged, compared to its average volume of 1,045,818. The stock has a market cap of $155.05 million, a price-to-earnings ratio of -0.66 and a beta of -0.41. Lyell Immunopharma, Inc. has a fifty-two week low of $0.48 and a fifty-two week high of $3.15. The firm has a fifty day moving average price of $0.61 and a two-hundred day moving average price of $0.87.

Lyell Immunopharma (NASDAQ:LYEL) last issued its earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). The firm had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. As a group, research analysts predict that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.

Institutional Investors Weigh In On Lyell Immunopharma

A number of institutional investors and hedge funds have recently modified their holdings of LYEL. Decheng Capital LLC acquired a new position in Lyell Immunopharma during the fourth quarter worth approximately $7,622,000. Foresite Capital Management V LLC acquired a new position in shares of Lyell Immunopharma during the 4th quarter worth approximately $5,205,000. venBio Partners LLC bought a new stake in Lyell Immunopharma in the 4th quarter valued at $4,545,000. Renaissance Technologies LLC lifted its holdings in Lyell Immunopharma by 716.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,612,146 shares of the company’s stock valued at $1,032,000 after purchasing an additional 1,414,746 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new position in Lyell Immunopharma during the fourth quarter worth $887,000. 66.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “neutral” rating and issued a $1.00 price objective on shares of Lyell Immunopharma in a report on Thursday, March 13th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.